Bicyclic heterocycles as FGFR inhibitors

A method of inhibiting or ameliorating cancer in a patient, comprising administering to said patient a therapeutically effective amount of 2′-(2,6-difluoro-3,5-dimethoxyphenyl)-6′-[(2-morpholin-4-ylethyl)amino]-1′,2′-dihydro-3′H-spiro[cyclopropane-1,4′-[2,7]naphthyridin]-3′-one, or a pharmaceutically acceptable salt thereof, and an additional therapeutic agent, wherein the cancer is associated with abnormal expression or activity of FGFR enzymes or FGFR ligands, and wherein the cancer is selected from kidney cancer, gastric cancer, esophageal cancer, lung cancer, breast cancer, bladder cancer, head and neck cancer, ovarian cancer, cervical cancer, glioblastoma, and endometrial cancer.